Transforming the production method of life-saving pharmaceuticals
ExCulture has an exclusive licence to a mixed culture fermentation bioprocess technology from TU Delft that we are developing as a novel method for producing heparin-like compounds.
To future-proof the supply chains of life-saving medications such as heparin through the implementation of a bio-based, animal-free approach.
1 out of 3 patients
Admitted to the hospital require treatment with heparin - for example in the case of cardiovascular disease, surgical procedures, and hemodialysis
1 billion pigs
Are required yearly to meet the global demand for heparin as it is produced as an extract of the mucosal lining of pig intestines
80 % of global heparin supply comes from China
This poses many risks to supply security, safety and sustainability for geopolitical reasons as well as environmental such as the recurring outbreaks of African Swine Fever
FDA listed shortage
Of heparin since 2017 however there is an increasing demand for heparin for its standard applications as well as new indications
Eliminates the dependency on animal products
Is a natural, sustainable production method for the recovery of scarce high-value material (including heparin-like compounds) from abundant sources
Has high scalability potential
Is not dependent on geographical location